Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015. 

A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA).  

Combined cranial and large vessel ultrasound and PET/CT provided excellent accuracy for the diagnosis of giant cell arteritis (GCA).

Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" documentopens in a new tab or window from the European Alliance of Associations for Rheumatology (EULAR).

A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).

A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Day 4 was a half day closeout to the EULAR 2023 Congress.

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial intelligence in medicine and rheumatology.

EULAR 2023 launched today to crowds of attendees.  The opening Plenary session and presidential address by Dr.

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.

Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling. 

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.